BKBess M. Kew

Bess M. Kew

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bess M. Kew has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Symptom Overlap Between Depression and Borderline Personality Disorder: A Network Analysis

    by Bess M. Kew, Nathan J. Monk, Tamlin S. Conner, Chris Frampton, Roger T. Mulder, Richard J. Porter, Janet D. Carter, Jennifer Jordan, Virginia V. W. McIntosh, Katie M. Douglas

    Major depression (MD) is a serious mental health disorder projected to become the leading cause of global disability by 2030. Borderline personality disorder (BPD) frequently co‐occurs with MD. Individuals with both conditions often experience prolonged recovery times and exhibit high levels of suicidal behaviour. Network theory and its application, network analysis, presents a novel framework for conceptualising and understanding the comorbidity between MD and BPD. This network analysis aims to identify influential symptoms within a BPD/MD network and explore the clinical relevance of these relationships. Data from 548 participants were pooled from four clinical trials run between 1994 and 2013 at the Department of Psychological Medicine, University of Otago, Christchurch, New Zealand. All participants were diagnosed with current MD (as part of major depressive disorder or bipolar II disorder). Baseline MD and BPD symptom data from trial entry assessments were entered into a cross‐sectional network analysis. A further network analysis was estimated with the addition of three covariates (age, gender and depression severity) alongside the MD and BPD symptoms. Network analyses identified several connecting symptoms between MD and BPD. After controlling for depression severity, BPD symptoms of identity disturbance and unstable relationships had unique and robust relationships with MD suicidal ideation and behaviours. Further exploration of these bridge relationships found that participants who exhibited identity disturbance were almost three times more likely to have reported a previous suicide attempt. Results from this study have implications for risk assessment and treatment of individuals with comorbid MD and BPD.


  • Open Access

    Investigation of a broad‐spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient–drug interactions

    by Bess M. Kew, Matthew P. Doogue, Richard McNeill, Mei Zhang, Julia J. Rucklidge, Christopher M. Frampton, Roger T. Mulder, Ben Beaglehole

    Aims: Daily broad‐spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad‐spectrum micronutrients in mental health care, there have not been any formal evaluations of potential interactions. Our objective was to evaluate a broad‐spectrum micronutrient formula as a potential precipitant of pharmacokinetic drug–drug interactions through inhibition or induction of cytochrome P450 (CYP) enzymes. Methods: This was a single‐centre pharmacokinetic study. Twelve healthy participants received broad‐spectrum micronutrients for 14 days (Days 1–14). Participants were administered a ‘cocktail’ of selective CYP probes midazolam 2 mg (CYP3A), dextromethorphan 30 mg (CYP2D6), losartan 25 mg (CYP2C9), omeprazole 20 mg (CYP2CI9) and caffeine 100 mg (CYP1A2) on Day 0 and Day 14, before taking and while taking broad‐spectrum micronutrients. Plasma drug concentrations were measured at baseline and for 8 h following cocktail administration. AUC, C max and T max were compared before and after broad spectrum micronutrient administration using paired t­ tests. Results: Pre‐ and post‐micronutrient geometric means (SD) for AUC 0‐8h (μg*h/L) were: midazolam 25 (13) and 26 (14), P = 0.60; dextromethorphan 25 (99) and 19 (110), P = 0.46; losartan 219 (105) and 205 (76), P = 0.20; omeprazole 474 (394) and 402 (342), P = 016; and caffeine 13 800 (5400) and 12 800 (3500), P = 0.79. There were no statistically significant changes in geometric means of probe C max , or T max for any of the study drugs. Conclusions: Broad‐spectrum micronutrients are unlikely to be a major precipitant of pharmacokinetic drug–drug interactions.


  • Open Access

    The changing doctor–patient relationship in psychiatry: observations on recent trends in autism, attention-deficit hyperactivity disorder, gender dysphoria and mental distress

    by Ben Beaglehole, Bridgette Thwaites, Bess Kew, Roger Mulder

    This editorial highlights increasing prevalence and treatment rates of apparently disparate disorders. We ask whether cross-disorder factors including greater mental health literacy, social media and a shift to psychiatric explanations for distress contribute to these trends. We highlight a consequence: the changing doctor–patient relationship and its impacts.


  • Open Access

    Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review

    by Bess M. Kew, Richard J. Porter, Katie M. Douglas, Paul Glue, Charlotte L. Mentzel, Ben Beaglehole

    Background: Ketamine is an effective short-term treatment for a range of psychiatric disorders. A key question is whether the addition of psychotherapy to ketamine treatment improves outcomes or delays relapse. Aim: To identify all studies combining psychotherapy with ketamine for the treatment of psychiatric disorders to summarise their effects and make recommendations for future research. Method: The review protocol was prospectively registered with PROSPERO (registration number CRD42022318120). Potential studies were searched for in MEDLINE, Embase, PsycINFO, SCOPUS, the Cochrane library and Google Scholar. Eligible studies combined ketamine and psychotherapy for the treatment of psychiatric disorders and did not use case reports or qualitative designs. Key findings relating to psychotherapy type, diagnosis, ketamine protocol, sequencing of psychotherapy and study design are reported. Risk of bias was assessed using modified Joanna Briggs critical appraisal tools. Results: Nineteen studies evaluating 1006 patients were included in the systematic review. A variety of supportive individual and group, manualised and non-manualised psychotherapies were used. The majority of studies evaluated substance use disorders, post-traumatic stress disorder and treatment-resistant depression. Ketamine protocols and sequencing of ketamine/psychotherapy treatment varied substantially between studies. Outcomes were largely positive for the addition of psychotherapy to ketamine treatment. Conclusion: The combination of psychotherapy and ketamine offers promise for the treatment of psychiatric disorders, but study heterogeneity prevents definitive recommendations for their integration. Larger randomised controlled trials using manualised psychotherapies and standardised ketamine protocols are recommended to clarify the extent to which the addition of psychotherapy to ketamine improves outcomes over ketamine treatment alone.